The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.

The goal of this randomized clinical trial is to investigate whether pressurized intraperitoneal chemotherapy (PIPAC), delivered immediately after minimally invasive D2 gastrectomy and repeated 6-8 weeks later, improves 12-month peritoneal disease-free survival in patients with high-risk gastric adenocarcinoma when compared to standard treatment.

NCT Number	NCT06295094
Lead Sponsor	Odense University Hospital Collaborators: Karolinska University Hospital
Conditions	Gastric Cancer, Chemotherapy, Adjuvant, Peritoneal Metastases, Minimally Invasive Surgical Procedures
Enrollment	264 participants
Start Date	2024-09
Primary Completion	2027-01 (estimated)
Study Completion	2028-01 (estimated)
Updated on ClinicalTrials.gov	2024-03-06